Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 8/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278917 | 0.88 | MAOB (0.49) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL6296027 | 0.84 | VCAM1 (0.43) | CYP19A1GAA | |
| SCHEMBL17752288 | 0.83 | FNTA (0.57) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL21327476 | 0.82 | POLB (0.61) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL490118 | 0.81 | CYP19A1 (0.48) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL26936315 | 0.81 | FNTA (0.49) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL5112608 | 0.79 | POLB (0.49) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL7074501 | 0.77 | CYP19A1 (0.48) | CYP19A1FNTAFNTBPGGT1BAR | |
| SCHEMBL19474587 | 0.76 | MAPK1 (0.35) | FNTAFNTBPGGT1BARMAOA | |
| SCHEMBL26936308 | 0.75 | ALDH1A1 (0.49) | CYP19A1FNTAFNTBPGGT1BAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10787441-B2 | Hepatitis C virus inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184476-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017181383-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017181383-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184476-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787441-B2 | Hepatitis C virus inhibitors | HAVCR2, FABP1, SLC10A1 | CYP19A1 1083/4885FNTA 367/4885FNTB 234/4885 |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, FABP1, SLC10A1 | CYP19A1 1083/4885FNTA 367/4885FNTB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.